Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Inclusion Criteria:

* Patient with non-resectable metastatic colorectal cancer with histological or cytological documentation of adenocarcinoma of the colon or rectum.
* Patient in third line or fourth line of treatment for metastatic colorectal cancer.
* Patient with measurable lesions according to RECIST criteria (version 1.1).
* Patient with ECOG equal to or less than 2.
* Patient with adequate organ function
* Other inclusion criteria may also apply

Exclusion Criteria:

* Prior treatment with masitinib, or any other tyrosine kinase inhibitor for the treatment of malignancy, except regorafenib.
* More than 3 prior chemotherapy regimens for metastatic colorectal cancer.
* Pregnant, intent to be pregnant, or nursing female patient
* Patient with any chronic inflammatory bowel disease
* Patient treated for a cancer other than colorectal cancer within five years before enrollment, with the exception of basal cell carcinoma or cervical cancer in situ.
* Other exclusion criteria may also apply